IRadimed Corporation logo IRMD - IRadimed Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 2
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $120.00 DETAILS
HIGH: $120.00
LOW: $120.00
MEDIAN: $120.00
CONSENSUS: $120.00
UPSIDE: 30.29%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Strong
Trading 67.5% above fair value
Current Price $92.10
Bear Case $32.50 64.7% downside ($32.50 - $92.10) / $92.10 = -64.7% 12% stage 1 growth, 11% discount
Fair Value $54.98 40.3% downside ($54.98 - $92.10) / $92.10 = -40.3% 19% stage 1 growth, 11% discount
Bull Case $82.78 10.1% downside ($82.78 - $92.10) / $92.10 = -10.1% 25% stage 1 growth, 11% discount

Adjust Assumptions

19.3%
11.0%
3.0%

Key Value Driver

FCF growth rate (19% base case)

Terminal Value % of EV 46%
Implied Market Multiple 75.1x

Plain-Language Summary

Using a two-stage FCF DCF with 19% growth decelerating over 15 years, discounted at 11%, the base-case intrinsic value is $54.98 per share.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions